Alkem Laboratories on Tuesday (12 April) announced that its facility at St. Louis in USA has received an establishment inspection report (EIR) from the US drug regulator.
The US Food and Drug Administration (USFDA) has issued an establishment inspection report (EIR) for the manufacturing facility located at St. Louis in USA and the inspection has now been closed by the USFDA.Alkem Laboratories' consolidated net profit surged 88.6% to Rs 381.98 crore on a 13.3% jump in net sales to Rs 2,181.84 crore in Q3 December 2019 over Q3 December 2018.
Alkem Laboratories is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The company operates through two segments: pharmaceutical and investing.
Shares of Alkem Laboatories were down 0.94% to Rs 2,571.40 on BSE. The stock traded in the range of Rs 2,526.85 to Rs 2,597.10 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
